

(FILE 'HOME' ENTERED AT 09:17:02 ON 01 NOV 2006)

FILE 'REGISTRY' ENTERED AT 09:17:17 ON 01 NOV 2006

L1 STRUCTURE UPLOADED
L2 2 S L1 SSS SAM
L3 STRUCTURE UPLOADED
L4 0 S L3
L5 46 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:20:12 ON 01 NOV 2006

L6 18 S L5
L7 1 S L6 AND ((SEPTIC OR TOXIC) (W) SHOCK)

FILE 'REGISTRY' ENTERED AT 09:20:50 ON 01 NOV 2006

SEL L5

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 09:21:29 ON 01 NOV 2006
SEA SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

1 FILE BIOSIS
2 FILE CAPLUS
1 FILE EMBASE
1 FILE IFIPAT
1 FILE MEDLINE
1 FILE PASCAL
1 FILE SCISEARCH
2 FILE TOXCENTER
3 FILE USPATFULL
1 FILE WPIDS
1 FILE WPINDEX

L8 QUE SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE' ENTERED AT 09:22:54 ON 01 NOV 2006

L9 5 S SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

L10 4 DUP REM L9 (1 DUPLICATE REMOVED)

FILE 'USPATFULL, PCTFULL, EPFULL' ENTERED AT 09:23:50 ON 01 NOV 2006

L11 7 S SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

FILE 'CAPLUS' ENTERED AT 09:24:37 ON 01 NOV 2006

L12 1 S L5 AND SEPSIS

FILE 'REGISTRY' ENTERED AT 09:17:17 ON 01 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 31 OCT 2006 HIGHEST RN 911785-87-0
DICTIONARY FILE UPDATES: 31 OCT 2006 HIGHEST RN 911785-87-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10807961lipidgeneric.str



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 27 34 35
36 37 38 39 40 41 42

ring nodes :

21 22 23 24 25 26 28 29 30 31 32 33

chain bonds :

1-2 1-19 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14
14-15 15-16 16-17 17-18 17-20 20-21 23-34 24-41 25-42 26-27 27-28 30-36
31-38 32-39 33-40 34-35 36-37

ring bonds :

21-22 21-26 22-23 23-24 24-25 25-26 28-29 28-33 29-30 30-31 31-32 32-33

exact/norm bonds :
1-19 17-20 20-21 21-22 21-26 22-23 23-24 24-25 24-41 25-26 25-42 26-27
27-28 28-29 28-33 29-30 30-31 31-32 31-38 32-33 32-39 33-40
exact bonds :
1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15
15-16 16-17 17-18 23-34 30-36 34-35 36-37

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom
27:CLASS 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS 35:CLASS
36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS

L1 STRUCTURE uploaded

=> d 11
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam
SAMPLE SEARCH INITIATED 09:17:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2671 TO 4249
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d 12 scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 9-Octadecenamide, 17-[(2-O- β -D-glucopyranosyl- β -D-
glucopyranosyl)oxy]-N-[2-(4-methoxyphenyl)ethyl]-, (9Z,17S)- (9CI)
MF C39 H65 N O13

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1) :1

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 9-Octadecenamide, 17-[(2-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-N-hexyl-, (9Z)- (9CI)
 MF C36 H67 N O12

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Program Files\Stnexp\Queries\10807961lipidgeneric2.str



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 27 34 35
 36 37 38 39 40 41 42 43

ring nodes :

21 22 23 24 25 26 28 29 30 31 32 33

chain bonds :

1-2 1-19 1-43 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13
 13-14 14-15 15-16 16-17 17-18 17-20 20-21 23-34 24-41 25-42 26-27 27-28
 30-36 31-38 32-39 33-40 34-35 36-37

ring bonds :

21-22 21-26 22-23 23-24 24-25 25-26 28-29 28-33 29-30 30-31 31-32 32-33

exact/norm bonds :

1-19 1-43 17-20 20-21 21-22 21-26 22-23 23-24 24-25 24-41 25-26 25-42
 26-27 27-28 28-29 28-33 29-30 30-31 31-32 31-38 32-33 32-39 33-40

exact bonds :

1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15
 15-16 16-17 17-18 23-34 30-36 34-35 36-37

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
 18:CLASS 19:CLASS 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom
 27:CLASS 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS 35:CLASS
 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS

L3 STRUCTURE UPLOADED

=> s 13
 SAMPLE SEARCH INITIATED 09:19:21 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2671 TO 4249
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s 13 sss full
FULL SEARCH INITIATED 09:19:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3239 TO ITERATE


100.0% PROCESSED 3239 ITERATIONS 46 ANSWERS
SEARCH TIME: 00.00.01

L5 46 SEA SSS FUL L3

=> d 15 scan

L5 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 9-Octadecenoic acid, 17-[[6-O-acetyl-2-O-(6-O-acetyl- β -D-glucopyranosyl)- β -D-glucopyranosyl]oxy] - (9CI)
MF C34 H58 O15

Absolute stereochemistry.
Double bond geometry unknown.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L5 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN α -D-Galactopyranose, 1,2:3,4-bis-O-(1-methylethylidene)-, (9Z,17S)-17-[[6-O-acetyl-2-O-(6-O-acetyl- β -D-glucopyranosyl)- β -D-glucopyranosyl]oxy]octadecanoate (9CI)
MF C46 H76 O20


Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

LS 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 9-Octadecenoic acid, 17-[(6-O-acetyl-2-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-, ethyl ester, (9Z,17S)- (9CI)
 MF C34 H60 O14


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 9-Octadecenoic acid, 17-[(6-O-acetyl-2-O-(6-O-acetyl-beta-D-glucopyranosyl)-beta-D-glucopyranosyl)oxy]-, ethyl ester (9CI)
 MF C36 H62 O15


Absolute stereochemistry.
 Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 9-Octadecenoic acid, 17-[(2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-, ethyl ester, (9Z)- (9CI)
 MF C32 H58 O13

Absolute stereochemistry.
 Double bond geometry as shown.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN α -D-Galactopyranose, 1,2:3,4-bis-O-(1-methylethyldene)-,
 (9Z,17S)-17-[[2-O-(6-O-acetyl- β -D-glucopyranosyl)- β -D-
 glucopyranosyl]oxy]-9-octadecenoate (9CI)
 MF C44 H74 O19

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		168.70	168.91

FILE 'CAPLUS' ENTERED AT 09:20:12 ON 01 NOV 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Nov 2006 VOL 145 ISS 19
 FILE LAST UPDATED: 30 Oct 2006 (20061030/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s 15
L6      18 L5

=> s 16 and ((septic or toxic) (w) shock
      12885 SEPTIC
      246933 TOXIC
      140395 SHOCK
      6169 (SEPTIC OR TOXIC) (W) SHOCK
L7      1 L6 AND ((SEPTIC OR TOXIC) (W) SHOCK)
```

=> d 17 ti abs bib

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treatment and prophylaxis of sepsis and septic shock
with sophorolipids
AB A composition for the prophylaxis or treatment of humans or animals for
septic shock and sepsis using a mixture of sophorolipids
is disclosed. The in vivo expts. demonstrated that sophorolipids have a
protective effect against ongoing endotoxic shock. I.p. injection of
sophorolipids 1.5 h after galactosamine-LPS treatment resulted in 53%
lower mortality than that observed among pos. control mice.
AN 2004:905607 CAPLUS
DN 141:355428
TI Treatment and prophylaxis of sepsis and septic shock
with sophorolipids
IN Gross, Richard A.
PA USA
SO U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004214795	A1	20041028	US 2004-807961	20040324
	WO 2005094268	A2	20051013	WO 2005-US10060	20050324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-457070P	P	20030324		
	US 2004-807961	A2	20040324		

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.05	177.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'REGISTRY' ENTERED AT 09:20:50 ON 01 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 31 OCT 2006 HIGHEST RN 911785-87-0
DICTIONARY FILE UPDATES: 31 OCT 2006 HIGHEST RN 911785-87-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

<-----User Break----->

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

FULL ESTIMATED COST ENTRY SESSION
15.62 193.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -0.75

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 09:21:29 ON 01 NOV 2006

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s sophorolipid and ((septic or toxic) (w) shock)

1 FILE BIOSIS
2 FILE CAPLUS

1 FILE EME

SEARCHED...

1	FILE	IFIPAT
1	FILE	MEDLINE
1	FILE	PASCAL
1	FILE	SCISEARCH
2	FILE	TOXCENTER
3	FILE	USPATFULL
1	FILE	WRIDS

66 FILES SEARCHED

1. FILE WRINDEX

11 FILES HAVE ONE OR MORE ANSWERS. 68 FILES SEARCHED IN STNINDEX

18 QUE SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

=> file biosis medline caplus embase
COST IN U.S. DOLLARS

COST IN U.S. DOLLARS		SINCE FILE	TOTAL
		ENTRY	SESSION
FULL ESTIMATED COST		1.22	194.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		SINCE FILE	TOTAL
		ENTRY	SESSION
CA SUBSCRIBER PRICE		0.00	-0.75

FILE 'BIOSIS' ENTERED AT 09:22:54 ON 01 NOV 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 09:22:54 ON 01 NOV 2006

FILE 'CAPLUS' ENTERED AT 09:22:54 ON 01 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 09:22:54 ON 01 NOV 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s sophorolipid and ((septic or toxic) (w) shock).
L9 5 SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

=> dup rem 19
PROCESSING COMPLETED FOR L9
L10 4 DUP REM L9 (1 DUPLICATE REMOVED)

=> d 110 1-4 ti

L10 ANSWER 1 OF 4 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Sophorolipid treatment decreases inflammatory cytokine
expression in an in vitro model of experimental sepsis.

L10 ANSWER 2 OF 4 MEDLINE on STN DUPLICATE 1
TI Sophorolipids block lethal effects of septic shock in
rats in a cecal ligation and puncture model of experimental sepsis.

L10 ANSWER 3 OF 4 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN
TI Sophorolipids block lethal effects of septic shock in
rats in a cecal ligation and puncture model of experimental sepsis.

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treatment and prophylaxis of sepsis and septic shock
with sophorolipids

=> d 110 1-4 ti abs bib

L10 ANSWER 1 OF 4 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Sophorolipid treatment decreases inflammatory cytokine
expression in an in vitro model of experimental sepsis.

AB Sophorolipids are a class of membrane-derived glycolipids that have wide
ranging potential as treatment in clinical practice. Previous data from
our laboratory show that in vivo sophorolipid therapy decreases
sepsis related mortality in experimental models. In this study we
investigated the effects of sophorolipid treatment on cytokine
production in an in vitro model of experimental sepsis. LPS stimulated
rat alveolar macrophage cells (NR8383) were cultured in the presence or
absence of sophorolipids for 12, 24, 36; and 48 hr. RNA was harvested
from each group and assayed for cytokine expression using multiplex PCR.
Statistical analyses were performed comparing the LPS treated group (L)
with the LPS + sophorolipid treated group (L+S). TNF- α , a
proinflammatory cytokine known to play a pivotal role in septic
shock was significantly decreased in the L+S group compared to the
L group at 12-24 hr, but trended upward at 36-48hr. Pro-inflammatory
cytokines IL-1 α and IL-1 β followed the same pattern. IL-1 receptor
antagonist (RA), which provides a protective effect in experimental
sepsis, also showed decreased expression in the L+S compared to L group at
12-24 hr and an upward trend at 36-48hr. Similar expression pattern was
found with IL-10, which may affect Th1/Th2 type T cell responses.
Sophorolipid treatment decreases expression of important
pro-inflammatory cytokines in an in vitro cellular sepsis model and this
immunomodulation may be responsible, in part, for sophorolipid
mediated decreases in sepsis related mortality. Sophorolipid
treatment may delay or prevent sepsis progression by allowing host
response immune mechanisms to exert their protective effects.

AN 2006:344333 BIOSIS
DN PREV200600343465
TI Sophorolipid treatment decreases inflammatory cytokine expression in an in vitro model of experimental sepsis.
AU Mueller, Cathy M. [Reprint Author]; Lin, Yin-yao; Viterbo, Domenico; Pierre, Joelle; Murray, Shirley A.; Shah, Vishat; Gross, Richard; Schulze, Robert; Zenilman, Michael E.; Bluth, Martin H.
CS Suny Downstate Med Ctr, Brooklyn, NY 11203 USA
SO FASEB Journal, (MAR 6 2006) Vol. 20, No. 4, Part 1, pp. A204.
Meeting Info.: Experimental Biology 2006 Meeting. San Francisco, CA, USA. April 01 -05, 2006. Amer Assoc Anatomists; Amer Physiol Soc; Amer Soc Biochem & Mol Biol; Amer Soc Investigat Pathol; Amer Soc Nutr; Amer Soc Pharmacol & Expt Therapeut.
CODEN: FAJOEC. ISSN: 0892-6638.
DT Conference; (Meeting).
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 12 Jul 2006
Last Updated on STN: 12 Jul 2006

L10 ANSWER 2 OF 4 MEDLINE on STN DUPLICATE 1
TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.
AB OBJECTIVE: Sophorolipids, a family of natural and easily chemoenzymatically modified microbial glycolipids, are promising modulators of the immune response. The potential of the therapeutic effect of sophorolipids was investigated in vivo in a rat model of sepsis and in vitro by analysis of nitric oxide and cytokine production. DESIGN: Prospective, randomized animal study. SETTING: Experimental laboratory. SUBJECTS: Male Sprague-Dawley rats, 200-240 g. INTERVENTIONS: Intra-abdominal sepsis was induced in vivo in 166 rats via cecal ligation and puncture (CLP); 60 rats were used to characterize the model. The remaining rats were treated with sophorolipids or vehicle (dimethylsulfoxide [DMSO]/physiologic saline) by intravenous (iv) tail vein or intraperitoneal (IP) injection immediately post-CLP (25/group). Survival rates were compared at 36 hrs after surgery. In vitro, macrophages were cultured in lipopolysaccharide (LPS) +/- sophorolipid and assayed for nitric oxide (NO) production and gene expression profiles of inflammatory cytokines. In addition, splenic lymphocytes isolated from CLP rats +/- sophorolipid treatment (three per group) were analyzed for cytokine production by RNase protection assay. MEASUREMENTS AND MAIN RESULTS: CLP with 16-gauge needles optimized sepsis induction and resultant mortality. Sophorolipid treatment improved rat survival by 34% (iv) and 14% (IP) in comparison with vehicle controls ($p < .05$ for iv treatment). Sophorolipids decreased LPS-induced macrophage NO production by 28% ($p < .05$). mRNA expression of interleukin (IL)-1beta was downregulated by 42.5 +/- 4.7% ($p < .05$) and transforming growth factor (TGF)-beta1 was upregulated by 11.7 +/- 1.5% ($p < .05$) in splenocytes obtained 6 hrs postsophorolipid treatment. LPS-treated macrophages cultured 36 hrs with sophorolipids showed increases in mRNA expression of IL-1alpha (51.7%), IL-1beta (31.3%), and IL-6 (66.8%) ($p < .05$). CONCLUSIONS: Administration of sophorolipids after induction of intra-abdominal sepsis significantly decreases mortality in this model. This may be mediated in part by decreased macrophage NO production and modulation of inflammatory responses.

AN 2005693126 MEDLINE
DN PubMed ID: 16374148
TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.
AU Bluth Martin H; Kandil Emad; Mueller Catherine M; Shah Vishal; Lin Yin-Yao; Zhang Hong; Dresner Lisa; Lempert Leonid; Nowakowski Maja; Gross Richard; Schulze Robert; Zenilman Michael E
CS SUNY Downstate Medical Center, Department of Surgery, Brooklyn, NY 11203, USA.. martin.bluth@downstate.edu

SO Critical care medicine, (2006 Jan) Vol. 34, No. 1, pp. 188-95.
Journal code: 0355501. ISSN: 0090-3493.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 200601

ED Entered STN: 30 Dec 2005
Last Updated on STN: 21 Jan 2006
Entered Medline: 20 Jan 2006

L10 ANSWER 3 OF 4 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.

AB Objective: Sophorolipids, a family of natural and easily chemoenzymatically modified microbial glycolipids, are promising modulators of the immune response. The potential of the therapeutic effect of sophorolipids was investigated *in vivo* in a rat model of sepsis and *in vitro* by analysis of nitric oxide and cytokine production. Design: Prospective, randomized animal study. Setting: Experimental laboratory. Subjects: Male Sprague-Dawley rats, 200-240 g. Interventions: Intra-abdominal sepsis was induced *in vivo* in 166 rats via cecal ligation and puncture (CLP); 60 rats were used to characterize the model. The remaining rats were treated with sophorolipids or vehicle (dimethylsulfoxide [DMSO]/physiologic saline) by intravenous (iv) tail vein or intraperitoneal (IP) injection immediately post-CLP (25/group). Survival rates were compared at 36 hrs after surgery. *In vitro*, macrophages were cultured in lipopolysaccharide (LPS) ± sophorolipid and assayed for nitric oxide (NO) production and gene expression profiles of inflammatory cytokines. In addition, splenic lymphocytes isolated from CLP rats ± sophorolipid treatment (three per group) were analyzed for cytokine production by RNase protection assay. Measurements and Main Results: CLP with 16-gauge needles optimized sepsis induction and resultant mortality. Sophorolipid treatment improved rat survival by 34% (iv) and 14% (IP) in comparison with vehicle controls ($p < .05$ for iv treatment). Sophorolipids decreased LPS-induced macrophage NO production by 28% ($p < .05$). mRNA expression of interleukin (IL)-1 β was downregulated by 42.5 ± 4.7% ($p < .05$) and transforming growth factor (TGF)- β 1 was upregulated by 11.7 ± 1.5% ($p < .05$) in splenocytes obtained 6 hrs postsophorolipid treatment. LPS-treated macrophages cultured 36 hrs with sophorolipids showed increases in mRNA expression of IL-1 α (51.7%), IL-1 β (31.3%), and IL-6 (66.8%) ($p < .05$). Conclusions: Administration of sophorolipids after induction of intra-abdominal sepsis significantly decreases mortality in this model. This may be mediated in part by decreased macrophage NO production and modulation of inflammatory responses. Copyright .COPYRGT. 2005 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins.

AN 2006010904 EMBASE

TI Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis.

AU Bluth M.H.; Kandil E.; Mueller C.M.; Shah V.; Lin Y.-Y.; Zhang H.; Dresner L.; Lempert L.; Nowakowski M.; Gross R.; Schulze R.; Zenilman M.E.

CS Dr. M.H. Bluth, Department of Surgery and Pathology, SUNY Downstate Medical Center, Box 40, 450 Clarkson Avenue, Brooklyn, NY 11203, United States. martin.bluth@downstate.edu

SO Critical Care Medicine, (2006) Vol. 34, No. 1, pp. E188.1-E188.8. .
Refs: 71
ISSN: 0090-3493 CODEN: CCMDC7

CY United States

DT Journal; Article

FS 004 Microbiology
030 Pharmacology
037 Drug Literature Index

048 Gastroenterology
 LA English
 SL English
 ED Entered STN: 19 Jan 2006
 Last Updated on STN: 19 Jan 2006

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Treatment and prophylaxis of sepsis and septic shock with sophorolipids
 AB A composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids is disclosed. The in vivo expts. demonstrated that sophorolipids have a protective effect against ongoing endotoxic shock. I.p. injection of sophorolipids 1.5 h after galactosamine-LPS treatment resulted in 53% lower mortality than that observed among pos. control mice.
 AN 2004:905607 CAPLUS
 DN 141:355428
 TI Treatment and prophylaxis of sepsis and septic shock with sophorolipids
 IN Gross, Richard A.
 PA USA
 SO U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004214795	A1	20041028	US 2004-807961	20040324
	WO 2005094268	A2	20051013	WO 2005-US10060	20050324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-457070P	P	20030324		
	US 2004-807961	A2	20040324		

=> file uspatfull pctfull epfull
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST SINCE FILE TOTAL
 ENTRY SESSION
 19.54 214.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE SINCE FILE TOTAL
 ENTRY SESSION
 -0.75 -1.50

FILE 'USPATFULL' ENTERED AT 09:23:50 ON 01 NOV 2006
 CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 09:23:50 ON 01 NOV 2006
 COPYRIGHT (C) 2006 Univentio

FILE 'EPPULL' ENTERED AT 09:23:50 ON 01 NOV 2006
 COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

=> s sophorolipid and ((septic or toxic) (w) shock)
 L11 7 SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

=> d 111 1-7 ti abs bib

L11 ANSWER 1 OF 7 USPATFULL on STN

TI Antifungal properties of various forms of sophorolipids
AB The preparation and use of 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Lactonic and Open ring 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Methyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Hexyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6"-acetate and Ethyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6',6"-diacetate sophorolipids as antifungal agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:190039 USPATFULL

TI Antifungal properties of various forms of sophorolipids

IN Gross, Richard A., Plainview, NY, UNITED STATES
Shah, Vishal, Plainsboro, NY, UNITED STATES

PI US 2005164955 A1 20050728

AI US 2004-20683 A1 20041222 (11)

RLI Continuation-in-part of Ser. No. WO 2003-US35871, filed on 6 Nov 2003, PENDING

DT Utility

FS APPLICATION

LREP TECHNOPROP COLTON, L.L.C., P O BOX 567685, ATLANTA, GA, 311567685, US

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 1204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 7 USPATFULL on STN

TI Spermicidal and virucidal properties of various forms of sophorolipids
AB A method for producing sophorolipids having spermicidal and/or antiviral properties by synthesizing the sophorolipid by fermentation of *Candida bombicola* in a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as a spermicidal and/or antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an spermicidal and/or antiviral agent, and sophorolipid compounds for use as spermicidal and/or antiviral agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:307825 USPATFULL

TI Spermicidal and virucidal properties of various forms of sophorolipids

IN Gross, Richard A., Plainview, NY, UNITED STATES
Shah, Vishal, Queens, NY, UNITED STATES
Doncel, Gustavo F., Norfolk, VA, UNITED STATES

PI US 2004242501 A1 20041202

AI US 2004-804778 A1 20040319 (10)

PRAI US 2003-456208P 20030320 (60)

DT Utility

FS APPLICATION

LREP TECHNOPROP COLTON, L.L.C., P O BOX 567685, ATLANTA, GA, 311567685

CLMN Number of Claims: 54

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 7 USPATFULL on STN

TI Treatment and prophylaxis of sepsis and septic shock

AB A method and composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:274293 USPATFULL

TI Treatment and prophylaxis of sepsis and septic shock

IN Gross, Richard A., Plainview, NY, UNITED STATES

PI US 2004214795 A1 20041028

AI US 2004-807961 A1 20040324 (10)

PRAI US 2003-457070P 20030324 (60)

DT Utility

FS APPLICATION

LREP TECHNOPROP COLTON, L.L.C., P O BOX 567685, ATLANTA, GA, 311567685

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 654

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 7 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN ANTIFUNGAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS

TIFR PROPRIETES ANTIFONGIQUES DE DIVERSES FORMES DE SOPHOROLIPIDES

ABEN The preparation and use of 17-L-[(2'-O-ss-D-glucopyranosyl-p-D-­glucopyranosyl)-oxy]-cis-9-octadecenoate, Lactonic and Open ring 17-L-[(2'-O-p-­D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Methyl 17-L-­[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Hexyl 17-L-[(2'-O-ss-D-glucopyranosyl-p-D-glucopyranosyl)-oxy]-cis-9­octadecenoate, Ethyl 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6"-acetate and Ethyl 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-­glucopyranosyl)-oxy]-cis-9-octadecenoate-6',6"-diacetate sophorolipids as antifungal agents.

ABFR L'invention se rapporte a la preparation et a l'utilisation de sophorolipides 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate de cycle ouvert et lactonique, 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate de methyle, 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate d'ethyle, 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate d'hexyle, 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6"-acetate d'ethyle et 17-L-[(2'-O-ss-D-glucopyranosyl-ss-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6',6"-diacetate d'ethyle en tant qu'agents antifongiques.

AN 2006069175 PCTFULL ED 20060704 EW 200626

TIEN ANTIFUNGAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS

TIFR PROPRIETES ANTIFONGIQUES DE DIVERSES FORMES DE SOPHOROLIPIDES

IN GROSS, Richard, A., 16 Northern Parkway East, Plainview, New York 11803, US;

SHAH, Vishal, 2513 Fox Run Drive, Plainsboro, New York 08536, US

PA POLYTECHNIC UNIVERSITY, Six Metro Tech Center, Brooklyn, New York 11201, US

AG COLTON, Laurence, P., Powell Goldstein LLP, 1201 West Peachtree Street, NW, Fourteenth Floor, Atlanta, Georgia 30309-3488; 30309-3488, US

LAF English

LA English

DT Patent

PI WO 2006069175 A2 20060629

DS W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR

CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY
 MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO
 RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ
 VC VN YU ZA ZM ZW
 RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT
 LU LV MC NL PL PT RO SE SI SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2005-US46426 A 20051222
 PRAI US 2004-11020683 20041222

L11 ANSWER 5 OF 7 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN TREATMENT AND PROPHYLAXIS OF SEPSIS AND SEPTIC SHOCK
 TIFR TRAITEMENT ET PROPHYLAXIE D'UNE SEPSIE ET D'UN CHOC SEPTIQUE
 ABEN A method and composition for the prophylaxis or treatment of humans or
 animals for
 septic shock and sepsis using a mixture of
 sophorolipids.
 ABFR La presente invention concerne une methode et une composition destinees
 a
 la prophylaxie ou au traitement d'une sepsie ou d'un choc septique chez
 des humains ou des animaux au moyen d'un melange de sophorolipides.
 AN 2005094268 PCTFULL ED 20051018 EW 200541
 TIEN TREATMENT AND PROPHYLAXIS OF SEPSIS AND SEPTIC SHOCK
 TIFR TRAITEMENT ET PROPHYLAXIE D'UNE SEPSIE ET D'UN CHOC SEPTIQUE
 IN GROSS, Richard, A., 16 Northern Parkway East, Plainview, NY 11803, US
 [US, US]
 PA POLYTECHNIC UNIVERSITY, Six MetroTech Center, Brooklyn, NY 11201, US
 [US, US], for all designates States except US;
 GROSS, Richard, A., 16 Northern Parkway East, Plainview, NY 11803, US
 [US, US], for US only
 AG COLTON, Laurence, P., Technoprop Colton LLC, P.O. Box 567685, Atlanta,
 GA 31156-7685, US
 LAF English
 LA English
 DT Patent
 PI WO 2005094268 A2 20051013
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
 MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE
 SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
 ZM ZW
 W-U: AE AL AM AT AZ BG BR BY BZ CN CO CR CZ DE DK EC EE EG ES
 FI GE HU JP KE KG KP KR KZ LS MD MX MZ NI PH PL PT RU SK
 SL TJ TR TT UA UG UZ YU
 RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT
 LU MC NL PL PT RO SE SI SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 RW-U (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2005-US10060 A 20050324
 PRAI US 2004-10/807,961 20040324

L11 ANSWER 6 OF 7 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN SPERMICIDAL AND VIRUCIDAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS
 TIFR PROPRIETES SPERMICIDES ET VIROCIDES DE DIFFERENTES FORMES DE
 SOPHOROLIPIDES
 ABEN A method for producing sophorolipids having spermicidal and/or antiviral
 properties by synthesizing the sophorolipid by fermentation of
Candida bombicola in a fermentation media to form a natural
 mixture of lactonic sophorolipids compounds and non-lactonic

sophorolipids compounds and utilizing the natural mixture as a spermicidal and/or antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an spermicidal and/or antiviral agent, and sophorolipid compounds for use as spermicidal and/or antiviral agents.

ABFR L'invention concerne un procede de production de sophorolipides ayant des proprietes spermicides et/ou antivirales par synthese du sophorolipide par fermentation of *Candida bombicola* dans un milieu de fermentation pour obtenir un melange naturel de composes sophorolipides lactoniques et de composes sophorolipidiques non lactoniques et utiliser ce melange naturel comme un agent spermicide et/ou antiviral, et/ou separer les sophorolipides lactoniques du melange naturel pour obtenir une fraction lactonique et melanger toutes les fractions restantes pour obtenir une fraction non lactonique et utiliser cette fraction lactonique et/ou la fraction non lactonique comme un agent spermicide et/ou antiviral. L'invention concerne egalement des composes sophorolipidiques a utiliser comme agents spermicides et/ou antiviraux.

AN 2005089522 PCTFULL ED 20051004 EW 200539
TIEN SPERMICIDAL AND VIRUCIDAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS
TIFR PROPRIETES SPERMICIDES ET VIROCIDES DE DIFFERENTES FORMES DE
SOPHOROLIPIDES
IN GROSS, Richard, A., 16 Northern Parkway East, Plainview, NY 11803, US [US, US];
SHAH, Vishal, 270-7 Union Turnpike, New Hyde Park, NY 11040, US [US, IN];
DONCEL, Gustavo, F., 608 Boissevain Avenue, Norfolk, VA 23507, US [US, US]
PA GROSS, Richard, A., 16 Northern Parkway East, Plainview, NY 11803, US [US, US];
SHAH, Vishal, 270-7 Union Turnpike, New Hyde Park, NY 11040, US [US, IN];
DONCEL, Gustavo, F., 608 Boissevain Avenue, Norfolk, VA 23507, US [US, US], for US only
AG COLTON, Laurence, P., Technoprop Colton LLC, P.O. Box 567685, Atlanta, GA 31156-7685, US
LAF English
LA English
DT Patent
PI WO 2005089522 A2 20050929
DS W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE
SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
ZM ZW
W-U: AE AL AM AT AZ BG BR BY BZ CN CO CR CZ DE DK EC EE EG ES
FI GE HU JP KE KG KP KR KZ LS MD MX MZ NI PH PL PT RU SK
SL TJ TR TT UA UG UZ YU
RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT
LU MC NL PL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
RW-U (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2005-US9486 A 20050318
PRAI US 2004-10/804,778 20040319

L11 ANSWER 7 OF 7 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN ANTIMICROBIAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS
TIFR PROPRIETES ANTIMICROBIENNES DE DIVERSES FORMES DE SOPHOROLIPIDES
ABEN The preparation and use of 17-L-[(2-&x2019;-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Lactonic and Open

ring 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Methyl 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Hexyl 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6'-acetate and Ethyl 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6',6''-diacetate sophorolipids are antibacterial, antiviral and/or anti-spermidical agents.

ABFR La presente invention concerne la preparation et l'utilisation de 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, de cycle ouvert et Lactonique 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Methyle 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyle 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Hexyle 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyle 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6'-acetate and ethyle 17-L-[(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6',6''-diacetate. Ces sophorolipides sont des agents antibacteriens, antiviraux et/ou spermicides.

AN 2004044216 PCTFULL ED 20040602 EW 200422

TIEN ANTIMICROBIAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS

TIFR PROPRIETES ANTIMICROBIENNES DE DIVERSES FORMES DE SOPHOROLIPIDES

IN GROSS, Richard, A., 16 Northern Parway East, Plainview, NY 11803, US [US, US];
SHAH, Vishal, 270-7 Union Turn Pike, New Hyde Park, NY 11040, US [IN, US]

PA POLYTECHNIC UNIVERSITY, Six Metrotech Center, Brooklyn, NY 11201, US [US, US], for all designates States except US;
GROSS, Richard, A., 16 Northern Parway East, Plainview, NY 11803, US [US, US], for US only;
SHAH, Vishal, 270-7 Union Turn Pike, New Hyde Park, NY 11040, US [IN, US], for US only

AG COLTON, Laurence, P., Technoprop Colton LLC, P.O. Box 567685, Atlanta, GA 31156-7685, US

LAF English

LA English

DT Patent

PI WO 2004044216 A1 20040527

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

RW (ARIPO): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2003-US35871 A 20031106

PRAI US 2002-60/424,271 20021106

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

16.16

230.50

FULL ESTIMATED COST

SINCE FILE

TOTAL

ENTRY

SESSION

0.00

-1.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 09:24:37 ON 01 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Nov 2006 VOL 145 ISS 19
FILE LAST UPDATED: 30 Oct 2006 (20061030/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 15 and sepsis
18 L5
14521 SEPSIS
L12 1 L5 AND SEPSIS

=> d l12 1 ti abs bib

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treatment and prophylaxis of sepsis and septic shock with
sophorolipids
AB A composition for the prophylaxis or treatment of humans or animals for septic
shock and sepsis using a mixture of sophorolipids is disclosed.
The in vivo expts. demonstrated that sophorolipids have a protective
effect against ongoing endotoxic shock. I.p. injection of sophorolipids
1.5 h after galactosamine-LPS treatment resulted in 53% lower mortality
than that observed among pos. control mice..

AN 2004:905607 CAPLUS

DN 141:355428

TI Treatment and prophylaxis of sepsis and septic shock with
sophorolipids

IN Gross, Richard A.

PA USA

SO U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004214795	A1	20041028	US 2004-807961	20040324
	WO 2005094268	A2	20051013	WO 2005-US10060	20050324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,				

MR, NE, SN, TD, TG
PRAI US 2003-457070P P 20030324
US 2004-807961 A2 20040324

=> log hold
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
5.15 235.65
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
CA SUBSCRIBER PRICE ENTRY SESSION
-0.75 -2.25

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:25:01 ON 01 NOV 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEX01623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 09:34:23 ON 01 NOV 2006
FILE 'CAPLUS' ENTERED AT 09:34:23 ON 01 NOV 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
5.15 235.65
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
CA SUBSCRIBER PRICE ENTRY SESSION
-0.75 -2.25

=> d his

(FILE 'HOME' ENTERED AT 09:17:02 ON 01 NOV 2006)

FILE 'REGISTRY' ENTERED AT 09:17:17 ON 01 NOV 2006

L1 STRUCTURE uploaded
L2 2 S L1 SSS SAM
L3 STRUCTURE uploaded
L4 0 S L3
L5 46 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:20:12 ON 01 NOV 2006

L6 18 S L5
L7 1 S L6 AND ((SEPTIC OR TOXIC) (W) SHOCK)

FILE 'REGISTRY' ENTERED AT 09:20:50 ON 01 NOV 2006
SEL L5

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 09:21:29 ON 01 NOV 2006
SEA SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

1 FILE BIOSIS

2 FILE CAPLUS
1 FILE EMBASE
1 FILE IFIPAT
1 FILE MEDLINE
1 FILE PASCAL
1 FILE SCISEARCH
2 FILE TOXCENTER
3 FILE USPATFULL
1 FILE WPIDS
1 FILE WPINDEX

L8 QUE SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE' ENTERED AT 09:22:54 ON 01 NOV 2006
L9 5 S SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)
L10 4 DUP REM L9 (1 DUPLICATE REMOVED)

FILE 'USPATFULL, PCTFULL, EPFULL' ENTERED AT 09:23:50 ON 01 NOV 2006
L11 7 S SOPHOROLIPID AND ((SEPTIC OR TOXIC) (W) SHOCK)

FILE 'CAPLUS' ENTERED AT 09:24:37 ON 01 NOV 2006
L12 1 S L5 AND SEPSIS

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.61	236.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-2.25

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:34:43 ON 01 NOV 2006